FASLG and myeloid sarcoma: Yet, clinical trials with injections of soluble myelin basic protein (MBP) [21], [22], native MBP peptide [23], or MBP altered peptide ligand (MBP-APL) [24], [25], for the treatment of MS have yielded disappointing results.